Katelyn T. Byrne, PhD, on the Clinical Impact of T-Cell Inflammation in the Tumor Microenvironment

April 14, 2021 By The ASCO Post Staff

Katelyn T. Byrne, PhD, of the Perelman School of Medicine at the University of Pennsylvania, discusses the first in-depth analysis of the impact of selicrelumab, an anti-CD40 antibody, which was found to enrich T cells in pancreatic tumors, activate the immune system, and alter the tumor stroma (Abstract CT005).

Related Content